Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC.
Ilié M, Mazières J, Chamorey E, Heeke S, Benzaquen J, Thamphya B, Boutros J, Tiotiu A, Fayada J, Cadranel J, Poudenx M, Moro-Sibilot D, Barlesi F, Thariat J, Clément-Duchêne C, Tomasini P, Hofman V, Marquette CH, Hofman P; STALKLUNG01 Study Consortium Investigators.
Ilié M, et al.
J Thorac Oncol. 2021 May;16(5):807-816. doi: 10.1016/j.jtho.2021.01.1617. Epub 2021 Feb 3.
J Thorac Oncol. 2021.
PMID: 33545389
Free article.
No significant association between the baseline levels or the dynamic change of CTCs and overall survival (hazard ratio = 0.59, 95% confidence interval: 0.24-1.5, p = 0.244) or progression-free survival (hazard ratio = 0.84, 95% confidence interval: 0.44-1.6, p = 0. …
No significant association between the baseline levels or the dynamic change of CTCs and overall survival (hazard ratio = 0.59, 95% c …